 UTRECHT, The Netherlands and PHILADELPHIA, April 27, 2022 GLOBE NEWSWIRE -- LAVA Therapeutics N.V. Nasdaq: LVTX , an immuno-oncology company focused on developing its proprietary GammabodyTM platform of bispecific gamma delta T cell engagers to transform the treatment of cancer, today announced the Company will present updated interim data from the dose escalation phase of the ongoing Phase 12a clinical trial of LAVA-051 in patients with relapsed or refractory chronic lymphocytic leukemia CLL and multiple myeloma MM at the 2022 American Society of Clinical Oncology ASCO Annual Meeting taking place in Chicago and virtually June 3-7, 2022. 